Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 1
1983 1
1984 1
1985 1
1987 2
1988 1
1989 2
1993 3
1994 1
1995 4
1996 1
1997 2
1998 5
1999 7
2000 2
2001 3
2002 3
2003 3
2004 7
2005 2
2006 2
2007 7
2008 2
2010 1
2013 3
2015 4
2016 2
2017 1
2019 2
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

73 results
Results by year
Filters applied: . Clear all
Page 1
DNA topoisomerase-targeting chemotherapeutics: what's new?
Cuya SM, Bjornsti MA, van Waardenburg RCAM. Cuya SM, et al. Among authors: bjornsti ma. Cancer Chemother Pharmacol. 2017 Jul;80(1):1-14. doi: 10.1007/s00280-017-3334-5. Epub 2017 May 20. Cancer Chemother Pharmacol. 2017. PMID: 28528358 Review.
Cancer therapeutics in yeast.
Bjornsti MA. Bjornsti MA. Cancer Cell. 2002 Oct;2(4):267-73. doi: 10.1016/s1535-6108(02)00160-5. Cancer Cell. 2002. PMID: 12398890 Free article. Review.
Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
van Waardenburg RC, de Jong LA, van Eijndhoven MA, Verseyden C, Pluim D, Jansen LE, Bjornsti MA, Schellens JH. van Waardenburg RC, et al. Among authors: bjornsti ma. J Biol Chem. 2004 Dec 24;279(52):54502-9. doi: 10.1074/jbc.M410103200. Epub 2004 Oct 6. J Biol Chem. 2004. PMID: 15471886 Free article.
The TOR pathway: a target for cancer therapy.
Bjornsti MA, Houghton PJ. Bjornsti MA, et al. Nat Rev Cancer. 2004 May;4(5):335-48. doi: 10.1038/nrc1362. Nat Rev Cancer. 2004. PMID: 15122205 Review. No abstract available.
Rapamycins: mechanism of action and cellular resistance.
Huang S, Bjornsti MA, Houghton PJ. Huang S, et al. Among authors: bjornsti ma. Cancer Biol Ther. 2003 May-Jun;2(3):222-32. doi: 10.4161/cbt.2.3.360. Cancer Biol Ther. 2003. PMID: 12878853 Review.
73 results